Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Promotes At-Home Blood-Pressure Checks

This article was originally published in PharmAsia News

Executive Summary

China's Ministry of Health is promoting at-home blood-pressure monitors as part of its national day to put a spotlight on the problem of life-threatening hypertension. The promotional effort includes having regional health departments offer consulting services to show residents how to measure their own pressure. The ministry estimates 200 million Chinese, 15 percent of the population, have high blood pressure, but only about 30 percent know it. Of the patients treated for high blood pressure in China, only 30 percent take their own measurements, compared with 75 percent in Italy. (Click here for more

You may also be interested in...



Takeda Introduces Vedolizumab In India Amid Signs of Gear Shift

Takeda launches blockbuster gastrointestinal drug vedolizumab in India, stepping up the tempo on the back of the local base provided by its acquisition of Shire. More expansion in the country appears to be in store for the Japanese firm.

QUOTED. 13 July 2020. Fred Colen.

The US FDA’s Circulatory System Devices advisory panel will meet on 27 October to discuss the review of the premarket approval application of Neovasc’s Reducer device, which is intended to treat angina. See what Neovasc’s CEO Fred Colen said about it here.

Quick Listen: Scrip’s Five Must-Know Things

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.

UsernamePublicRestriction

Register

LL1132247

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel